20/20 Biolabs prepares contingency plans for Ebola and Hantavirus testing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
May 22, 2026 8:31 AM EDTCompany to Draw on Substantial Experience with COVID Testing to Again Support Public Health Agencies if NeededÂ
GAITHERSBURG, Md., May 22, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc. (Nasdaq: AIDX) (20/20 Biolabs or the Company), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, announced that it is developing contingency plans to establish... More
